Ozempic Cost 2026: What You'll Actually Pay
List price is $1,027.51 per 28-day supply, the same for every dose strength. Actual cost depends on insurance, program eligibility, and which dose you're on.
Ozempic list price is $1,027.51 per 28-day supply, uniform across all doses (0.25, 0.5, 1, and 2 mg). Commercial insurance covering Ozempic for type 2 diabetes brings the Savings Card rate as low as $25 per month. Uninsured patients new to the NovoCare Pharmacy offer pay $199 per month for the first 2 fills of 0.25 or 0.5 mg (valid through June 30, 2026), then $349 per month for 0.25 to 1 mg or $499 per month for 2 mg. Federal insurance plans (Medicare, Medicaid, Tricare, VA) are excluded from the Savings Card, though Medicare Part D generally covers Ozempic for type 2 diabetes with prior authorization. The Novo Nordisk Patient Assistance Program offers free Ozempic for income-qualified uninsured patients. Patients seeking semaglutide for weight loss should use Wegovy, which has better insurance coverage and a $149 per month oral pill option.
Looking for semaglutide for weight loss? Use Wegovy, not Ozempic.
Wegovy is the same molecule as Ozempic (semaglutide), FDA-approved for chronic weight management. Insurance coverage is better, and NovoCare Pharmacy offers a cash-pay pill at $149/month that Ozempic does not.
Watching Ozempic's price?
One short email when manufacturer savings, payer coverage, or list price change.
What you pay, by scenario
The four common payment paths. Every price assumes the prescription is for FDA-approved use (type 2 diabetes, CV risk reduction in T2D, or CKD progression in T2D).
Savings Card applies at retail pharmacy. Maximum savings $100 per 1-month, $200 per 2-month, or $300 per 3-month supply. FDA-approved use only.
NovoCare Pharmacy self-pay. $199 for first 2 fills of 0.25 or 0.5 mg (ends June 30, 2026), then $349/mo for 0.25-1 mg or $499/mo for 2 mg.
Federal plans excluded from the Savings Card. Medicare Part D generally covers Ozempic for type 2 diabetes. Medicaid varies by state. MFN framework expected to cap Medicare copays at approximately $50/mo mid-2026.
Novo Nordisk Patient Assistance Program offers free Ozempic for income-qualified uninsured patients. Apply at novocare.com. No registration or monthly fees.
NovoCare new-patient intro at $199/mo ends June 30, 2026
Uninsured patients new to the NovoCare Pharmacy offer can pay $199 per month for the first 2 fills of 0.25 mg or 0.5 mg Ozempic through June 30, 2026. After 2 fills or the end date (whichever comes first), pricing reverts to $349 per month. The 1 mg and 2 mg doses are not eligible for the $199 intro rate.
Ozempic self-pay price by dose
Cash-pay pricing through NovoCare Pharmacy. List price is uniform across all doses; the self-pay rate tiers by dose and new-patient status.
Recent pricing news
Self-pay program launch, federal pricing framework, and patent timeline.
- November 17, 2025
Uninsured / self-pay introductory pricing launched
Novo Nordisk launched a limited-time introductory offer for uninsured and self-pay patients: $199/month for the first 2 monthly fills of Ozempic 0.25 mg or 0.5 mg. Valid November 17, 2025 through June 30, 2026. After the intro period, pricing reverts to $349/month for 0.25-1 mg or $499/month for 2 mg.
- November 6, 2025In progress
Most-Favored-Nation (MFN) pricing framework announced
Federal framework tying U.S. GLP-1 prices to lowest prices paid in comparable countries. Impact for Ozempic: Medicare Part D enrollees with type 2 diabetes coverage may see copays capped at approximately $50/month for eligible beneficiaries. Implementation in progress through 2026.
Status: Announced, implementation in progress.
- Invalid DateIn progress
Patent expiration (generic semaglutide eligibility)
Ozempic is patent-protected through 2031 per Novo Nordisk disclosures (per SingleCare reporting). Generic semaglutide cannot launch for Ozempic until the patent expires. No generic currently available or imminent.
Status: Anticipated. Monitor FDA approvals annually.
Related guides
Pricing verified against Novo Nordisk's official ozempic.com and novocare.com pages, cross-referenced with GoodRx, SingleCare, Optum Perks, and Weight Watchers. We do not accept payment for inclusion in any comparison. Medical content reviewed by Dr. Golsa Gholampour, MD, board-certified in obesity medicine. Quarterly re-verification scheduled.
